TEVA : Analysis & Opinions

  1. Pharma Industry Outlook: M&A, Licensing Abound - Industry Outlook

    November 18, 2014
    Pharma Industry Outlook: M&A, Licensing Abound - Industry Outlook
  2. 5 Drug Companies Profiting From Generics

    August 4, 2014
    Leading generic drug maker Teva Pharmaceutical (NYSE: TEVA) posted better-than-expected earnings last week and raised its ...
  3. Akorn Scores A Rare Win-Win Acquisition

    August 27, 2013
    Akorn builds value by buying Hi-Tech
  4. Novo Nordisk Getting Its Trial By Fire

    August 8, 2013
    Novo Nordisk is facing more challenges than it has in a while, but the growth remains strong.
  5. Does Amgen Deserve To Be Part Of The Biotech Bull Run?

    July 31, 2013
    Amgen is beating growth targets today, but fears about generics and a dull pipeline concern investors.
  6. Pfizer Gives Up Stake in Zoetis - Analyst Blog

    June 25, 2013
    Pfizer lowered its outlook for 2013 to reflect the impact of the divestment of the remaining stake in Zoetis.
  7. Big Pharma Faces 'Pay For Delay' Lawsuits

    June 21, 2013
    Unless you follow the pharmaceutical and biotech sectors, it’s likely that you’ve never heard of pay to delay. Instead of ...
  8. Adasuve Deal Is Very Good For Alexza, But What About Teva?

    May 9, 2013
    Teva's partnership with Alexza looks like an expensive gamble.
  9. Amgen Chased By The Bubble

    May 8, 2013
    Amgen really needs the pipeline to come through to support this valuation.
  10. Teva Still Too Cheap, But Still Too Uncertain

    May 3, 2013
    Teva's present-day momentum is weak, but the value could appeal to patient long-term investors.
  11. Natural Gas: A Big Win For Israel And Its Producers

    April 2, 2013
    While it’s a tech powerhouse, the natural gas game is quickly changing Israel’s economy for the good. The recent prolific ...
  12. MedTech Industry Stock Outlook - Jan 2013 - Zacks Analyst Interviews

    January 29, 2013
    We are in the midst of the fourth quarter earnings season and it is once again time to review the players in the worldwide ...
  13. Isis Pharma Updates on its Pipeline - Analyst Blog

    January 11, 2013
    Isis Pharmaceuticals, Inc. (ISIS) recently provided an update on its pipeline. Isis Pharma boasts of a robust pipeline. The ...
  14. Impax Launches Opana ER Generic - Analyst Blog

    January 7, 2013
    Global Pharmaceuticals, the generic division of Impax Laboratories, Inc. (IPXL), a specialty pharmaceutical company, recently ...
  15. Early Research Calls

    November 28, 2012
    New York, May 10th (TradersHuddle.com) - Research Analyst's early calls ahead of the bell. Prudential (NYSE:PRU) was upgraded ...
  16. Endo Health Solutions Needs Some Solutions Of Its Own

    November 7, 2012
    Can Endo reestablish itself as a quality healthcare name?
  17. Teva Likely To Tread Water Ahead Of New Strategy

    November 5, 2012
    Teva has restructuring and growth opportunities, but the risk is still elevated.
  18. New Ratings

    October 9, 2012
    New York, May 23rd (TradersHuddle.com) - These are the research analyst new ratings before the market open. Travelers (NYSE:TRV) ...
  19. Shire Settles Patent Dispute - Analyst Blog

    September 12, 2012
    Shire LLC, a subsidiary of Shire plc (SHPG) recently announced that it has entered into a settlement agreement with Anchen ...
  20. Strong Quarter at Shire - Analyst Blog

    August 2, 2012
    Shire plc (SHPG) posted second-quarter 2012 earnings (excluding special items) of $1.68 per American Depositary Share (ADS), ...
  21. Hi-Tech Pharmacal An Under Followed Name Worth Following

    July 12, 2012
    Hi-Tech Pharmacal gets little attention, but maybe it should.
  22. Aceto Looking At A Tough Future

    May 15, 2012
    Aceto is making sound moves, but the results need to be better.
  23. Covidien Reports, Ready To Spin Off Pharma

    May 4, 2012
    Covidien is looking to bridge its current valuation discount with a number of purer-play rivals.
  24. Growth Stocks Not Necessarily Risky

    March 8, 2012
    By looking at growth and value investment as two sides of the same coin, growth stocks like Disney aren't neccessarily risky ...
  25. Birth Control Subsidies Slashed: Will Big Pharma Take A Hit?

    March 6, 2012
    Several states have already slashed birth control subsidies. Learn how this will affect pharmaceutical stocks.
  26. Sanofi's Investment Prospects

    December 21, 2011
    Sanofi has emerged as an unheralded value in pharmaceuticals.
  27. Biogen Idec Has Built A Valuable Franchise

    November 1, 2011
    Biogen Idec is a go-to name in MS that carries a lot of value. A credible buy for those with longer horizons.
  28. VCA Antech Cut Down To Value

    October 31, 2011
    Once a go-go growth stock, a more reasonable valuation may give this stock new life.
  29. Betting On Healthcare's Growth Engine

    August 17, 2011
    In the wake of big pharma's patent cliff and slowing R&D spending, the biotech sector is looking good for investors. ...
  30. Teva And Mylan Show Some Value Remains In Generics

    August 4, 2011
    These two generics companies seem to be heading in opposite directions, but the values are similar.
  31. Should Investors Circle Back To Cubist?

    July 19, 2011
    Cubist is hitting its targets, but it needs a more exciting pipeline.
  32. The Best Of Both Worlds With The TICK

    July 5, 2011
    The TICK blends the best of both the developed and developing nations.
  33. Lipitor: Pfizer's Loss Is Watson's Gain

    June 10, 2011
    With Lipitor coming off its patent soon, there are a couple of drug companies looking to cash in on sales of the generic ...
  34. Teva And Cephalon Solve Each Other's Problems

    May 4, 2011
    Teva's acquisition of Cephalon is a logical deal that solves problems for each company.
  35. J&J Beats Analyst Expections, But Not Its Rivals

    April 25, 2011
    Tangible signs of sustained sales growth and consistent profit expansion are still absent at J&J.
  36. Embracing Tech With Israel

    April 13, 2011
    Israel is an emerging tech giant that could give the U.S. a run for its money, in the near future.
  37. Investing In Tech Through Emerging Markets

    March 23, 2011
    Moving beyond low-cost production foundries, many emerging markets such as israel, South Korea and Taiwan are experiencing ...
  38. Risk With Little Reward At Johnson & Johnson

    January 27, 2011
    A number of Johnson & Johnson rivals trade at equally appealing valuations and have their acts together in terms of product ...
  39. Soros' Top Picks

    January 12, 2011
    We take a peek at some of Soros Fund Management's top holdings to see what stocks George Soros has selected.
  40. Exploring Israel's Energy Potential

    January 7, 2011
    Israel recently made a major natural gas discovery. Find out how it will affect the industry.
  41. Expected Increase In Research And Development

    November 8, 2010
    Research & Development (R&D) is the key to success in the pharmaceutical industry, but just how much of an impact ...
  42. Another Setback For Roche Is Bad News For ImmunoGen

    August 27, 2010
    Roche suffers another setback to its key cancer franchise, while ImmunoGen faces a major delay in royalty payments.
  43. Investing In Israel

    July 29, 2010
    Israel offers solid fundamentals with the high-growth potential of a tech economy.
  44. Lilly's Top-Line Predicament

    April 21, 2010
    Eli Lilly will have more than $5 billion in annual free cash flow over the next few years to try and stem its top-line predicament. ...
  45. Three Middle Eastern Jewels

    April 9, 2010
    The Middle East offers opportunity for long-term investors in Egypt, Israel and Turkey.
  46. Forest Labs Faces Patent Expirations

    January 23, 2009
    This pharma faces patent expirations on its two key drugs, but its valuation reflects these risks and the firm has appealing ...
  47. 4 Double-Cross Buy Signs

    December 1, 2008
    Will the double crossover on MACD and Stochastic indicators trigger a move higher?
  48. Meet Teva, The Generic Giant

    May 15, 2008
    Success in generic drugs is all about high volume, low prices and global presence. Israel's Teva Pharmaceuticals has all ...
  49. Generic Manufacturers Go After Big Pharma

    March 14, 2007
    Generic drug manufacturers continue pose a potent threat to the established "big pharma" companies.
Trading Center